Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130234 · ClinicalTrials.gov registry record · Phase 2
Effect of Anti-IgE in Chronic Urticaria
A Phase 2 study of Urticaria, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00130234 is a Phase 2 study of Urticaria that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 54-participant average among 3 other Urticaria trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00130234, a Phase 2 study of Urticaria, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
Conditions Studied
Interventions
- DRUG Xolair® (Omalizumab)
Study Locations (1)
Maryland
- Johns Hopkins Asthma and Allergy Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130234
The ClinicalTrials.gov registry entry for NCT00130234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 3 other Urticaria trials with a reported enrollment target (63% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urticaria appearing as the primary indexed condition, and to 1 intervention - of which Xolair® (Omalizumab) is the first listed.
NCT00130234 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00130234 about?
NCT00130234 is a clinical study titled "Effect of Anti-IgE in Chronic Urticaria". This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
What is the current status of trial NCT00130234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-11. Estimated completion is 2007-09.
What conditions does trial NCT00130234 study?
This clinical trial studies the following conditions: Urticaria.
What interventions are being tested in trial NCT00130234?
The interventions under investigation include: Xolair® (Omalizumab) (DRUG).
Who is sponsoring clinical trial NCT00130234?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130234 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
COMPLETED · Phase 2
-
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
COMPLETED · Phase 1
-
Evaluating for Contact Allergies in Patients With Chronic Urticaria
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.